Aptus Capital Advisors, LLC Gilead Sciences, Inc. Transaction History

Aptus Capital Advisors, LLC

$6.27 Billion
Q3 2024

A detailed history of Aptus Capital Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Aptus Capital Advisors, LLC holds 8,263 shares of GILD stock, worth $776,308. This represents 0.01% of its overall portfolio holdings.

Number of Shares

8,263

Previous 7,954 3.88%

Holding current value

$776,308

Previous $545,000 26.97%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$66.59 - $83.99 $20,576 - $25,952	309 Added 3.88%	8,263 $692,000
Q2 2024 Jul 31, 2024	SELL	$63.15 - $72.88 $50,962 - $58,814	-807 Reduced 9.21%	7,954 $545,000
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $3.75 Million - $4.57 Million	-52,321 Reduced 85.66%	8,761 $641,000
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $5,861 - $6,647	-80 Reduced 0.13%	61,082 $4.95 Million
Q3 2023 Nov 08, 2023	SELL	$73.94 - $80.67 $164,442 - $179,410	-2,224 Reduced 3.51%	61,162 $4.58 Million
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $4.51 Million - $5.14 Million	59,286 Added 1446.0%	63,386 $4.89 Million
Q1 2023 May 09, 2023	SELL	$77.31 - $88.08 $40,974 - $46,682	-530 Reduced 11.45%	4,100 $340,000
Q4 2022 Feb 13, 2023	BUY	$62.32 - $89.47 $11,903 - $17,088	191 Added 4.3%	4,630 $397,000
Q3 2022 Nov 02, 2022	BUY	$59.54 - $68.01 $264,298 - $301,896	4,439 New	4,439 $274,000
Q2 2022 Jul 29, 2022	SELL	$57.72 - $65.01 $165,598 - $186,513	-2,869 Closed	0 $0
Q1 2022 May 04, 2022	BUY	$57.92 - $72.58 $166,172 - $208,232	2,869 New	2,869 $171,000
Q3 2020 Oct 19, 2020	SELL	$62.1 - $78.08 $166,862 - $209,800	-2,687 Closed	0 $0
Q2 2020 Jul 22, 2020	SELL	$72.34 - $84.0 $78,705 - $91,392	-1,088 Reduced 28.82%	2,687 $206,000
Q1 2020 May 07, 2020	SELL	$62.63 - $80.22 $186,637 - $239,055	-2,980 Reduced 44.12%	3,775 $282,000
Q4 2019 Feb 10, 2020	SELL	$61.62 - $67.78 $1.44 Million - $1.59 Million	-23,445 Reduced 77.63%	6,755 $438,000
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $283,232 - $312,639	-4,531 Reduced 13.05%	30,200 $1.91 Million
Q2 2019 Aug 13, 2019	BUY	$61.87 - $69.38 $196,684 - $220,559	3,179 Added 10.08%	34,731 $2.35 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $601,163 - $673,460	9,614 Added 43.82%	31,552 $2.05 Million
Q4 2018 Feb 12, 2019	BUY	$60.54 - $79.0 $1.33 Million - $1.73 Million	21,938 New	21,938 $1.37 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aptus Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aptus Capital Advisors, LLC with notifications on news.

Account

Aptus Capital Advisors, LLC Gilead Sciences, Inc. Transaction History